microbiome based News
-
Microviable will be attending Pharmabiotics Event 2022
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the ...
-
Dr. Warren Flood steps up as CEO of Bio-Me
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
By Bio-Me
-
Synbiotic Health Appoints Erin Vyhlidal as VP Corporate Finance
Microbiome-based ingredient company Synbiotic Health is pleased to announce the appointment of Erin Vyhlidal as Controller and Vice President, Corporate Finance. Vyhlidal is a CPA (inactive registrant) with twenty years’ experience in accounting. She previously oversaw a team of nine as VP Corporate Finance at Farmers National Company in Omaha, NE, after working at PricewaterhouseCoopers as ...
-
Evofuel to participate in the 2019 International Castor Oil Association - ICOA Conference
Evofuel Ltd., a company focused on securing the global demand for stable castor oil supply and a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that its CEO, Mr. Assaf Dotan, will present at 2019 ICOA Conference to take place on the 21st-23rd of May, 2019 in Dubrovnick, Croatia. Mr. Assaf Dotan will present the company’s new vision and branding. The ...
By Evogene Ltd.
-
Synbiotic Health Welcomes Kevin Hooper as Director of Business Development
Microbiome-based ingredient company Synbiotic Health announces that Kevin Hooper has joined the company as Director of Business Development. Hooper has more than 14 years’ experience in sales and business development, most recently at the global ingredient supplier IFF Health. At Synbiotic Health he will work with Steve Prescott, Senior Vice President of Business Development, to implement ...
-
Siolta Therapeutics Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Siolta Therapeutics to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products. This new addition brings MTIG's membership to five companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products. Siolta ...
-
Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based ...
-
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
April 22, 2022 at 8:00 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 22, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview with ...
-
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, ...
-
Evogene Financial Results for the First Quarter of 2019 Earnings Announcement Schedule
Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first quarter of 2019 on Tuesday, May 28, 2019. Dr. Arnon Heyman, CEO of Evogene’s cannabis subsidiary, Canonic, will join the conference call to discuss the company’s activity with highlights from ...
By Evogene Ltd.
-
Microbiotica Highly Commended at Cambridge Independent Science and Technology Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards. The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include a key new strategic ...
-
Bio-Me Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
By Bio-Me
-
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capital ...
-
Siolta Therapeutics Awarded NIH Grant
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding for the continued ...
-
Microbiotica Moves Into New Building at Chesterford Research Park
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. The Company’s operations were previously split between the Sulston Building and the BioData Innovation Centre at the Wellcome Genome Campus, before ...
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most recently it has been recognised for its collaboration with ...
-
Bio-Me represented with two presentations at the 6th Microbiome Movement – Drug Development Summit 2021
On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing ...
By Bio-Me
-
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
-
Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you